Can I continue HRT with a diagnosis of atrial fibrillation?

Question

Hello doctor,

I am a 58-year-old woman who was recently diagnosed with atrial fibrillation. I went through menopause approximately three years ago and am currently on hormone replacement therapy for hot flashes and mood swings. However, my cardiologist is concerned about continuing hormone replacement therapy with my new diagnosis of atrial fibrillation.

I am also taking blood thinners, which have caused heavier bleeding on the occasions when I still experience menstrual-like bleeding. I have been experiencing palpitations that seem to worsen during what used to be my menstrual week. Even though I no longer have regular periods, I still notice cyclical symptoms.

In addition, I am experiencing significant anxiety about my heart condition and am concerned whether this stress could be affecting my hormonal balance and overall women’s health. My mother had both heart disease and breast cancer, so I am worried about my personal risk for both conditions.

Is it safe to continue hormone replacement therapy with a diagnosis of atrial fibrillation?
Why do heart palpitations seem to worsen during what would have been the menstrual cycle?
How do blood thinners interact with any residual menstrual bleeding or hormone replacement therapy?
Can stress and anxiety related to a heart condition affect hormonal health?
What is the risk of breast cancer if hormone replacement therapy is continued or discontinued?
Are there alternative treatments for menopausal symptoms that would not negatively affect a heart condition?

Kindly advise.

Answer 1

Hello,

Welcome to icliniq.com.

I understand the concern.

You are currently in the postmenopausal phase, on hormone replacement therapy (HRT), recently diagnosed with atrial fibrillation (AFib), and taking anticoagulants (blood thinners). This combination requires careful medical evaluation, as it increases certain risks and makes management more complex.

In addition to the atrial fibrillation, palpitations may increase as a result of hormonal changes. This is true even after the period of menopause because hormone replacement therapy may have similar results.

I would recommend the following investigations:

Mammogram and clinical breast examination, especially considering the family history of breast cancer.
Pelvic ultrasonography (USG) should be performed if abnormal or if continued bleeding persists.
Hormonal profile assessment is clinically indicated.
Thyroid function tests to rule out thyroid dysfunction.
Cardiology evaluation and clearance are required before continuing any systemic estrogen therapy.

The following conditions need to be ruled out:

Anxiety-related palpitations.
Thyroid disorder.
Endometrial causes of postmenopausal bleeding.
Hormone-related rhythm sensitivity.

I would suggest the following measures:

The co-existence of atrial fibrillation and a family history of breast cancer makes it likely that a prolonged course of systemic hormone replacement therapy (especially those with estrogens) might be associated with an increased risk of cardiovascular and thromboembolic complications. The risk-benefit assessment is necessary.
Non-hormonal treatment for hot flashes includes SSRIs, such as Escitalopram and Sertraline; SNRIs, such as Venlafaxine and Desvenlafaxine; Gabapentin; and Clonidine. The use of the above-mentioned drugs requires a prescription.
Vaginal dryness can be managed with low-dose local vaginal estrogen preparations (which have lower systemic absorption compared to systemic therapy) or with non-hormonal lubricants and moisturizers.
For mood symptoms and anxiety, psychological therapy and non-hormonal medications are generally safer options than systemic hormone replacement therapy in this clinical scenario.

Preventive measures include regular breast cancer screening as recommended. Maintain a healthy body mass index (BMI) and engage in light to moderate regular exercise, as tolerated. Stress management techniques, as atrial fibrillation symptoms may worsen with anxiety.

A joint consultation with both a cardiologist and a gynecologist is advisable. Systemic hormone replacement therapy in a patient with atrial fibrillation who is on anticoagulants carries a higher risk and should be continued only after specialist evaluation. Mammogram results and relevant laboratory reports should be reviewed to guide further management decisions.

I hope you are satisfied with my answer. For further queries, you can consult me at iCliniq.

Thank you.